Portfolio company
Myricx Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
5 investors
Sectors
About
This biotechnology company develops antibody-drug conjugates using N-myristoyltransferase inhibitors to treat patients with cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Adcytherix
This biopharmaceutical company develops novel antibody-drug conjugates to treat various forms of cancer for patients with high unmet clinical needs.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
Mablink Bioscience
This biotechnology firm develops antibody-drug conjugates for pharmaceutical companies to treat cancer using a proprietary hydrophilic linker platform.
Profound Bio
This clinical-stage biotechnology company develops antibody-drug conjugates and targeted therapies for patients with solid tumors and hematological malignancies.
BiVictrix Therapeutics Plc
The company develops selective antibody-drug conjugates for the treatment of various cancers, including liquid and solid tumours, for the pharmaceutical and clinical sectors.
Adcendo
This clinical-stage biotechnology company develops antibody-drug conjugates to treat patients with various types of cancer and high unmet medical needs.
Nectin Therapeutics
This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.
Avidicure
This biotechnology company develops multifunctional antibody therapies for cancer patients to activate immune responses while reducing toxicity.
